AR034283A1 - Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento - Google Patents
Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamentoInfo
- Publication number
- AR034283A1 AR034283A1 ARP010106001A ARP010106001A AR034283A1 AR 034283 A1 AR034283 A1 AR 034283A1 AR P010106001 A ARP010106001 A AR P010106001A AR P010106001 A ARP010106001 A AR P010106001A AR 034283 A1 AR034283 A1 AR 034283A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- independently
- heteroaryl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Compuestos heterociclilindazol y azaindazol, que comprenden un compuesto de fórmula (1) en la cual Q es SO2, CO, CONR24, CSNR25 o CH2; W es N o CR6; X es N o CR7; Y es NR8 o CR9R10; n es 0 o un número entero de 1 o 2; Z es NR11 o CR12R13 con la condición que cuando n es 1, Q es SO2, CO o CH2, y W es CR6 entonces Z debe ser CR12R13 y con las condiciones adicionales que cuando Y es NR8 entonces Z debe ser CR12R13 y por lo menos uno de Y y Z deben ser NR8 o NR11; R1, R2 y R7 son cada uno independientemente H, halógeno, CN, OCO2R14, CO2R15, CONR29R30, CNR16NR17R18, SOmR19, NR20R21, OR22, COR23 o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido; R3, R4, R9, R10, R12 y R13 son cada uno independientemente H o un grupo alquilo C1-6 opcionalmente sustituido; R5 es un grupo alquilo C1-6, arilo o heteroarilo opcionalmente sustituido; m es 0 un número entero de 1o 2; R6 es H, halógeno, o un grupo alquilo C1-6; alcoxi C1-6, arilo o hereoarilo opcionalmente sustituido; R8 y R11 son cada uno independientemente H, CNR26NR27R28 o un grupo alquilo C1-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido; R14, R15, R22 y R22 son cada uno independientemente H o un grupo alquilo C1-6 alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo opcionalmente sustituido; R16, R17, R18, R20, R21, R26, R27, R28, R29 y R30 son cada uno independientemente H o alquilo C1-4; R19 es un grupo alquilo C1-6, arilo o heteroarilo opcionalmente sustituido. R24 y R25 son cada uno independientemente H o un grupo alquilo, C1-6, arilo o heteroarilo opcionalmente sustituido; y donde la línea punteada representa un enlace simple o un enlace doble; o los estereoisómeros del mismo o sus sales farmacéuticamente aceptables; un procedimiento para su preparación, composición farmacéutica que lo comprende y el uso del mismo para la fabricación de un medicamento para el tratamiento terapéutico de desórdenes relacionados con el sistema nervioso central o afectados por el receptor 5-HT6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25762700P | 2000-12-22 | 2000-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034283A1 true AR034283A1 (es) | 2004-02-18 |
Family
ID=22977057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010106001A AR034283A1 (es) | 2000-12-22 | 2001-12-21 | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento |
Country Status (20)
Country | Link |
---|---|
US (3) | US6767912B2 (es) |
EP (1) | EP1355904B1 (es) |
JP (1) | JP4307073B2 (es) |
KR (1) | KR20030062442A (es) |
CN (1) | CN1281605C (es) |
AR (1) | AR034283A1 (es) |
AT (1) | ATE368658T1 (es) |
BR (1) | BR0116323A (es) |
CA (1) | CA2432654A1 (es) |
DE (1) | DE60129746T2 (es) |
DK (1) | DK1355904T3 (es) |
EA (1) | EA200300717A1 (es) |
ES (1) | ES2290187T3 (es) |
HU (1) | HUP0400684A2 (es) |
IL (1) | IL156517A0 (es) |
MX (1) | MXPA03005432A (es) |
NO (1) | NO20032840L (es) |
PL (1) | PL363241A1 (es) |
WO (1) | WO2002051837A2 (es) |
ZA (1) | ZA200305622B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0116323A (pt) * | 2000-12-22 | 2003-10-14 | Wyeth Corp | Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6 |
CA2444095A1 (en) * | 2001-04-20 | 2002-10-31 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
IL158448A0 (en) * | 2001-04-20 | 2004-05-12 | Wyeth Corp | Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
KR100600240B1 (ko) * | 2001-06-07 | 2006-07-13 | 에프. 호프만-라 로슈 아게 | 5-ht6 수용체 친화도를 갖는 신규한 인돌 유도체 |
ES2307902T3 (es) * | 2002-02-12 | 2008-12-01 | N.V. Organon | Derivados de indolina e indol 1-arilsulfonil-3- sustituidos utilizados en el tratamiento de transtornos del sistema nervioso central. |
ES2201899B1 (es) | 2002-04-01 | 2005-06-01 | Almirall Prodesfarma, S.A. | Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos. |
JP4484108B2 (ja) * | 2002-05-16 | 2010-06-16 | 塩野義製薬株式会社 | Pgd2受容体拮抗作用を有する化合物 |
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
CA2515570A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
JP2006520796A (ja) * | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
WO2005005439A1 (en) * | 2003-07-09 | 2005-01-20 | Suven Life Sciences Limited | Benzothiazino indoles |
MXPA06000700A (es) * | 2003-07-23 | 2006-04-11 | Wyeth Corp | Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6. |
ES2222828B1 (es) * | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
ZA200600424B (en) | 2003-08-01 | 2007-05-30 | Genelabs Tech Inc | Bicyclic imidazol derivatives against flaviviridae |
DE10337184A1 (de) * | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
PT1704154E (pt) | 2004-01-02 | 2009-08-05 | Suven Life Sciences Ltd | Novos indeno[2,1a]indenos e isoindol[2,1-a]indóis |
WO2005066157A1 (en) * | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
CN1934111A (zh) | 2004-02-27 | 2007-03-21 | 霍夫曼-拉罗奇有限公司 | 杂芳基稠合的吡唑并衍生物 |
CN1922150A (zh) | 2004-02-27 | 2007-02-28 | 霍夫曼-拉罗奇有限公司 | 吲唑衍生物以及含有它们的药物组合物 |
RU2006134020A (ru) | 2004-02-27 | 2008-04-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Конденсированные производные пиразола |
EP2786995A1 (en) | 2004-03-30 | 2014-10-08 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
SG156685A1 (en) | 2004-07-27 | 2009-11-26 | Sgx Pharmaceuticals Inc | Fused ring heterocycle kinase modulators |
KR20070053237A (ko) | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 피롤로-피리딘 키나제 조절제 |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
EA012245B1 (ru) * | 2004-11-29 | 2009-08-28 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эд-Эл-Си | Терапевтические пиразоло[3,4-b]пиридины и индазолы |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
EP1915348A1 (en) * | 2005-08-15 | 2008-04-30 | Wyeth a Corporation of the State of Delaware | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2007021711A2 (en) * | 2005-08-15 | 2007-02-22 | Wyeth | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
JP2009506007A (ja) | 2005-08-25 | 2009-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | p38MAPキナーゼ阻害剤及びその使用方法 |
US20080275058A1 (en) * | 2005-09-15 | 2008-11-06 | Korea Research Institute Of Chemical Technology | N-Substituted-1H-Quinoline-2,4-Diones, Preparation Method Thereof, And Pharmaceutical Composition Containing The Same |
WO2007031838A1 (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
EP1945213A4 (en) * | 2005-10-24 | 2009-12-02 | Janssen Pharmaceutica Nv | MODULATORS OF THE R3-PIPERIDINE-4-YL-INDOLE ORL-1 RECEPTOR |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US7696229B2 (en) | 2006-02-17 | 2010-04-13 | Memory Pharmaceuticals Corporation | Compounds having 5-HT6 receptor affinity |
KR20090006148A (ko) * | 2006-04-05 | 2009-01-14 | 와이어쓰 | 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체 |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
NZ577798A (en) | 2006-12-21 | 2012-04-27 | Vertex Pharma | 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
MX2009008324A (es) * | 2007-02-16 | 2009-10-20 | Memory Pharm Corp | Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6. |
MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
US8242280B2 (en) | 2007-04-10 | 2012-08-14 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
JP2010528037A (ja) * | 2007-05-24 | 2010-08-19 | メモリー・ファーマシューティカルズ・コーポレイション | 5−ht6受容体親和性を有する4’置換化合物 |
KR20100053626A (ko) * | 2007-08-15 | 2010-05-20 | 메모리 파마슈티칼스 코포레이션 | 5-ht6 수용체 친화성을 나타내는 3'-치환된 화합물 |
SI2247589T1 (sl) | 2007-11-05 | 2013-03-29 | Merck Patent Gmbh | Derivati 7-azaindola kot selektivni inhibitorji 11-beta-hidroksisteroidne dehidrogenaze tipa 1 |
EA019819B1 (ru) | 2008-05-23 | 2014-06-30 | ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении |
US8546576B2 (en) | 2008-06-06 | 2013-10-01 | Sk Biopharmaceuticals Co., Ltd. | 3 or 4-substituted piperidine compounds |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
HUE031048T2 (en) | 2009-06-17 | 2017-06-28 | Vertex Pharma | Influenza virus replication inhibitors |
WO2011143430A1 (en) | 2010-05-12 | 2011-11-17 | Abbott Laboratories | Indazole inhibitors of kinase |
CA2822057A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
CN105849105B (zh) | 2013-11-13 | 2018-02-13 | 沃泰克斯药物股份有限公司 | 制备流感病毒复制抑制剂的方法 |
CA2930103A1 (en) | 2013-11-13 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
SG11201610407QA (en) | 2014-07-08 | 2017-01-27 | Sunshine Lake Pharma Co Ltd | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
CN109678776B (zh) * | 2019-01-24 | 2020-07-14 | 苏州大学 | 3-芳基琥珀酰亚胺类化合物的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670447A (en) * | 1983-08-22 | 1987-06-02 | Hoechst-Roussel Pharmaceuticals Inc. | Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles |
US5196425A (en) * | 1988-09-02 | 1993-03-23 | Janssen Pharmaceutica N.V. | Antihypertensive 3-piperidinyl-indazole derivatives |
US5409941A (en) | 1992-02-03 | 1995-04-25 | Pfizer Inc. | 5-heteroyl indole derivatives |
ZA951822B (en) * | 1994-12-23 | 1996-09-26 | Glaxo Group Ltd | Chemical compounds |
WO1997049698A1 (en) * | 1996-06-21 | 1997-12-31 | Glaxo Group Limited | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders |
CN1289479C (zh) * | 1996-11-26 | 2006-12-13 | Nps艾里利克斯有限公司 | 作为5-ht1d受体配位体的5-环吲哚化合物 |
ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
GB9805716D0 (en) * | 1998-03-17 | 1998-05-13 | Merck Sharp & Dohme | Therapeutic agents |
US6133287A (en) | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
US6251893B1 (en) | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
US6066637A (en) | 1998-06-19 | 2000-05-23 | American Home Products Corporation | Indolyl derivatives as serotonergic agents |
MXPA01010655A (es) * | 1999-04-21 | 2002-11-04 | Allelix Biopharma | Compuestos de piperidin-indol que tienen afinidad por 5-ht6. |
US6191141B1 (en) | 1999-08-12 | 2001-02-20 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
BR0116323A (pt) * | 2000-12-22 | 2003-10-14 | Wyeth Corp | Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6 |
-
2001
- 2001-12-11 BR BR0116323-0A patent/BR0116323A/pt not_active IP Right Cessation
- 2001-12-11 PL PL01363241A patent/PL363241A1/xx unknown
- 2001-12-11 ES ES01986147T patent/ES2290187T3/es not_active Expired - Lifetime
- 2001-12-11 KR KR10-2003-7008394A patent/KR20030062442A/ko not_active Application Discontinuation
- 2001-12-11 EP EP01986147A patent/EP1355904B1/en not_active Expired - Lifetime
- 2001-12-11 EA EA200300717A patent/EA200300717A1/ru unknown
- 2001-12-11 CA CA002432654A patent/CA2432654A1/en not_active Abandoned
- 2001-12-11 WO PCT/US2001/047935 patent/WO2002051837A2/en active IP Right Grant
- 2001-12-11 CN CNB018228283A patent/CN1281605C/zh not_active Expired - Fee Related
- 2001-12-11 JP JP2002552932A patent/JP4307073B2/ja not_active Expired - Fee Related
- 2001-12-11 IL IL15651701A patent/IL156517A0/xx unknown
- 2001-12-11 DE DE60129746T patent/DE60129746T2/de not_active Expired - Lifetime
- 2001-12-11 AT AT01986147T patent/ATE368658T1/de not_active IP Right Cessation
- 2001-12-11 DK DK01986147T patent/DK1355904T3/da active
- 2001-12-11 HU HU0400684A patent/HUP0400684A2/hu unknown
- 2001-12-11 MX MXPA03005432A patent/MXPA03005432A/es active IP Right Grant
- 2001-12-20 US US10/028,168 patent/US6767912B2/en not_active Expired - Fee Related
- 2001-12-21 AR ARP010106001A patent/AR034283A1/es unknown
-
2003
- 2003-06-20 NO NO20032840A patent/NO20032840L/no not_active Application Discontinuation
- 2003-07-21 ZA ZA200305622A patent/ZA200305622B/en unknown
- 2003-10-23 US US10/691,937 patent/US6903112B2/en not_active Expired - Fee Related
-
2005
- 2005-01-20 US US11/039,344 patent/US20050124603A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL156517A0 (en) | 2004-01-04 |
DE60129746D1 (de) | 2007-09-13 |
WO2002051837A2 (en) | 2002-07-04 |
CA2432654A1 (en) | 2002-07-04 |
US20020198213A1 (en) | 2002-12-26 |
BR0116323A (pt) | 2003-10-14 |
US6767912B2 (en) | 2004-07-27 |
DK1355904T3 (da) | 2007-10-15 |
US6903112B2 (en) | 2005-06-07 |
PL363241A1 (en) | 2004-11-15 |
HUP0400684A2 (hu) | 2004-07-28 |
ZA200305622B (en) | 2004-10-21 |
US20040092526A1 (en) | 2004-05-13 |
KR20030062442A (ko) | 2003-07-25 |
US20050124603A1 (en) | 2005-06-09 |
MXPA03005432A (es) | 2003-09-10 |
NO20032840L (no) | 2003-08-20 |
EA200300717A1 (ru) | 2003-12-25 |
EP1355904A2 (en) | 2003-10-29 |
JP2004518668A (ja) | 2004-06-24 |
NO20032840D0 (no) | 2003-06-20 |
ES2290187T3 (es) | 2008-02-16 |
JP4307073B2 (ja) | 2009-08-05 |
CN1281605C (zh) | 2006-10-25 |
CN1553910A (zh) | 2004-12-08 |
ATE368658T1 (de) | 2007-08-15 |
WO2002051837A3 (en) | 2003-01-16 |
DE60129746T2 (de) | 2008-04-30 |
EP1355904B1 (en) | 2007-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
ECSP045519A (es) | Nuevos derivados de quinuclidina-amida | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
NO20060682L (no) | Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer | |
UY28578A1 (es) | Derivados de amida | |
AR044526A1 (es) | Compuestos triciclicos moduladores de receptor nuclear de hormonas esteroides, composiciones farmaceuticas que los comprenden y su uso para la fabricacion de un medicamento. | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
NO20060865L (no) | Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer | |
NO171365C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater | |
AR034284A1 (es) | Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso central | |
DE602006005685D1 (de) | Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden | |
SE9904508D0 (sv) | New compounds | |
AR056086A1 (es) | DERIVADOS DE 4-FENIL-PIRIMIDINA-6-SUSTITUíDA-2-CARBONITRILO, COMPOSICION FARMACEUTICA QUE LOS COMPRENDE Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON CATEPSINA K Y CATEPSINA S | |
AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
AR032778A1 (es) | Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento | |
BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |